ClinicalTrials.Veeva

Menu

Safety and PK of Multiple Doses of MT1988

M

Monument Therapeutics

Status and phase

Completed
Phase 1

Conditions

Healthy Volunteer

Treatments

Drug: Placebo
Drug: MT1988

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

The goal of this clinical trial is to assess the tolerability and amount of drug in the blood when four dose levels of MT1988 are administered for 14 days to healthy volunteers. The main question it aims to answer is:

  • what side effects are seen while administering MT1988 for 14 days?
  • how much of MT1988 can be measured in the blood at the beginning and end of administering MT1988 for 14 days?

Researchers will include a placebo arm (dummy drug) to compare the side effects.

Participants will:

  • take MT1988 every day for 14 days
  • visit the clinic once per week for assessments
  • keep a diary to record information between clinic appointments.

Enrollment

42 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy volunteers
  • providing informed consent
  • for females of child-bearing potential with fertile male partner - willing to comply with contraception requirements

Exclusion criteria

  • no current or past condition which may compromise the study objectives or participant safety
  • no clinically significant finding at screening, including physical examination, blood tests, medical history, concomitant medication
  • history of drug abuse or dependence within the previous 2 years

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

42 participants in 5 patient groups, including a placebo group

MT1988 Dose 1
Experimental group
Description:
MT1988 Dose Level 1 (oral, twice daily)
Treatment:
Drug: MT1988
MT1988 Dose 2
Experimental group
Description:
MT1988 Dose Level 2 (oral, twice daily)
Treatment:
Drug: MT1988
MT1988 Dose 3
Experimental group
Description:
MT1988 Dose Level 3 (oral, twice daily)
Treatment:
Drug: MT1988
MT1988 Dose 4
Experimental group
Description:
MT1988 Dose Level 4 (oral, twice daily)
Treatment:
Drug: MT1988
Placebo
Placebo Comparator group
Description:
Placebo (oral, twice daily)
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Chief Development Officer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems